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Abstract
Botulinum toxins, i.e. BoNT/A to/G, include the most toxic substances known. Since botulism is a potentially fatal
neuroparalytic disease with possible use as a biowarfare weapon (Centers for Disease Control and Prevention category A
bioterrorism agent), intensive efforts are being made to develop vaccines or neutralizing antibodies. The use of active
fragments from non-human immunoglobulins (F(ab’)2, Fab’, scFv), chemically modified or not, may avoid side effects, but
also largely modify the in vivo half-life and effectiveness of these reagents. We evaluated the neutralizing activity of several
monoclonal anti-BoNT/A antibodies (mAbs). F(ab’)2 fragments, native or treated with polyethyleneglycol (PEG), were
prepared from selected mAbs to determine their half-life and neutralizing activity as compared with the initial mAbs. We
compared the protective efficiency of the different biochemical forms of anti-toxin mAbs providing the same neutralizing
activity. Among fourteen tested mAbs, twelve exhibited neutralizing activity. Fragments from two of the best mAbs (TA12
and TA17), recognizing different epitopes, were produced. These two mAbs neutralized the A1 subtype of the toxin more
efficiently than the A2 or A3 subtypes. Since mAb TA12 and its fragments both exhibited the greatest neutralizing activity,
they were further evaluated in the therapeutic experiments. These showed that, in a mouse model, a 2- to 4-h interval
between toxin and antitoxin injection allows the treatment to remain effective, but also suggested an absence of
correlation between the half-life of the antitoxins and the length of time before treatment after botulinum toxin A
contamination. These experiments demonstrate that PEG treatment has a strong impact on the half-life of the fragments,
without affecting the effectiveness of neutralization, which was maintained after preparation of the fragments. These
reagents may be useful for rapid treatment after botulinum toxin A contamination.
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Introduction
Seven serologically distinct botulinum toxins, BoNT/A to/G,
are produced by different strains of the Gram-positive, spore-
forming anaerobic bacterium Clostridium botulinum. These neuro-
toxins are the most toxic substances known, being, for example,
100,000 times more toxic than sarin [1]. Three main forms
of human botulism generally associated with toxinotypes A, B
and E have been described: i) foodborne botulism, ii) intestinal
colonization (infant botulism and foodborne illness in adults) due
to toxin production in the intestine after ingestion of Clostridium
botulinum spores, and iii) wound botulism [2]. Botulism cases are
rare but can be life-threatening and the recovery period requires
intensive care and can take several months. Vaccination against
botulism is available and consists of a long-lasting inoculation
protocol which has only been used for people at high risk of
exposure and not for whole populations. Since no drugs allow
prevention or treatment, toxin-neutralizing antibodies were
developed for prophylactic or therapeutic treatment [3]. These
antitoxins were obtained after immunization of several species:
horse [4], goat [5], mouse [6–7], and human [8]. How-
ever, the use of antitoxin from nonhomologous species can
generate side effects including anaphylactic shock [9] and the
production of human anti-species antibodies. Moreover, human
antitoxin antibodies from immunized volunteers also have
limitations related to their small-scale production and the risk
of infectious disease transmission. Different strategies have been
developed to circumvent these limitations using phage display
libraries from immunized mice or humans [10,11] or using
immunoglobulin fragments, like F(ab’)2 [12,13], which are less
immunogenic. However, these fragments have short in vivo half-
lives, which must be taken into account considering the expected
duration of antitoxin activity. Several reports have shown that
linking polyethylene glycol (PEG) molecules to F(ab’)2 fragments
(pegylated fragments) can overcome this problem by extending in
vivo half-life [14–17].
In the present study, the neutralizing potency of 14 monoclonal
antibodies (mAbs) raised against BoNT type A was estimated.
F(ab’)2 fragments from the most efficient mAbs were then
produced and further modified by PEG treatment. The
neutralizing effects and the in vivo half-lives of the fragments,
pegylated or not, were characterized before finally evaluating
their efficiency for therapeutic treatment of mice challenged with
BoNT/A.
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Materials and Methods
Reagents
Unless otherwise stated, all reagents were from Sigma (St. Louis,
MO). C. botulinum cultures require handling precautions, due to
their toxicity. Appropriate laboratory attire should be worn,
including a lab coat, gloves and safety glasses. BoNT-contaminat-
ed materials were inactivated by immersion in 5% sodium
hypochlorite solution for 24 h. C. botulinum strains were grown in
TGY (30 g/l trypticase; 5 g/l glucose; 20 g/l yeast extract, 0.5 g/l
cysteine hydrochloride; pH 7.5) in anaerobic conditions for 4 days
at 37uC. The cultures were acidified at pH 3.5 with sulfuric acid,
centrifuged, and the pellet was extracted with 0.2 M sodium
phosphate buffer pH 6.0 as previously described [18]. The ex-
tracted material constitutes the toxin stock.
Recombinant Hc BoNT/A1 fragment, corresponding to the
binding domain of the neurotoxin type A1, was prepared as
previously described [19].
N-Hydroxysuccinimidyl ester of methoxy poly(ethylene glycol)
butanoic acid (abbreviated as NHS-PEG) corresponding to a
30 kDa linear PEG was from Nektar Therapeutics (Huntsville,
AL).
For immunoassays, all reagents were diluted in EIA buffer
(0.1 M phosphate buffer pH 7.4 containing 0.15 M NaCl, 0.1%
bovine serum albumin (BSA) and 0.01% sodium azide). Plates
were washed with washing buffer (0.01 M phosphate pH 7.4
buffer containing 0.05% Tween 20). Ellman’s medium used to
reveal the activity of acetylcholinesterase (AChE), an enzyme used
as marker in the immunoassays, comprised a mixture of 7.5
1024 M acetylthiocholine iodide (enzyme substrate) and 2.5
1024 M 5,59-dithiobis(2-nitrobenzoic acid) (DTNB) (reagent for
thiol colorimetric measurement) in 0.1 M phosphate buffer,
pH 7.4. Enzymatic activity was expressed in Ellman units (EU).
One EU is defined as the amount of enzyme producing an
absorbance increase of one unit during 1 min in 1 ml of medium,
for an optical path length of 1 cm; it corresponds to about 8 ng of
enzyme.
Apparatus
Immunometric assay was performed using Titertek microtitra-
tion equipment from Labsystem (Helsinki, Finland), including an
automatic plate washer (Washer 120) and an automatic plate
reader (Multiskan BICHROMATIC). 96-well microtitre plates
(Maxisorp) were from Nunc (Roskilde, Denmark).
Monoclonal antibodies
Monoclonal antibodies (mAbs) were raised against recombinant
Hc BoNT/A1 as previously described [20]. The relative epitopes
of these mAbs and their subsequent classification in five epitopic
groups were determined using complementary tests. The mAbs
selected for their neutralizing activity were affinity-purified on
protein A (Prosep-A High capacity, Millipore, Billerica, USA) and
the F(ab’)2 fragments obtained by treatment with pepsin in acidic
medium [21]. Purity of mAbs and F(ab’)2 was assessed by
polyacrylamide gel electrophoresis (SDS-PAGE) in denaturing
and reducing conditions using the phast System apparatus (GE
Healthcare, Bucks, UK) with 10–15% polyacrylamide gels,
following the manufacturer’s instructions.
F(ab’)2 pegylation
After preparation, the F(ab’)2 were dialyzed against borate
buffer 0.02 M pH 9 before conjugation to PEG using a 3-fold
molar excess of PEG (15 nmoles) added to 500 mg (500 ml of a
1 mg/ml solution) of dialyzed F(ab’)2 (5 nmoles). After 30 min at
room temperature with gentle agitation, F(ab’)2 were purified by
cation exchange chromatography to remove unreacted PEG and
to separate the different F(ab’)2 species (nonpegylated, mono-
pegylated and multipegylated F(ab’)2). A MacroCap SP column
(GE Healthcare) (10.561 cm) was used with an AKTÄ system (GE
Healthcare) and equilibrated with buffer A (0.02 M acetate buffer
pH 5) at a flow rate of 1 ml/min. The reaction mixture was
filtered through a 0.2 mm filter and loaded onto the column. After
washing the column with 17 ml of buffer A at 1 ml/min, the
pegylated F(ab’)2 was eluted using successive gradient steps of
12 ml each at 2, 3, 4, 5 and 25% of buffer B (0.02 M acetate buffer
pH 5+1 M NaCl) at 1 ml/min. The column was regenerated with
17 ml of buffer B at 1 ml/min. During the chromatography,
fractions of 1 ml were collected and the absorbance was monitored
at 280 nm. Fractions corresponding to each peak were pooled and
analyzed by SDS-PAGE.
Monoclonal antibody complementary tests and epitope
mapping
The simultaneous binding of the different mAbs to BoNT/A
was analyzed in immunometric tests, with one mAb immobilized
on the solid phase while the other was used as a biotin-labeled
tracer. Experiments were performed as follows: 10 ng/ml BoNT/
A and 100 ml of a 100 ng/ml biotin-labeled mAb solution were
added to microtiter plate wells coated with one of the mAbs. After
18-h incubation at 4uC, the plates were washed before adding
200 ml/well of AChE-labeled streptavidin conjugate (2 EU/ml).
After a further 1-h incubation at room temperature followed by
several washings, 200 ml of Ellman’s medium were added to each
well. After 1-h incubation, the absorbance was measured at
414 nm (Table S1).
For each pair of mAbs two combinations are possible. The
absence of specific signals for both combinations means that these
mAbs have the same or close epitopes.
Enzyme immunoassay of anti-BoNT/A1 mAbs and their
fragments in mouse plasma
All experiments were performed in accordance with French and
European Community guidelines for laboratory animal handling.
The pharmacokinetic studies were performed on mice using
mouse monoclonal antibodies. The specific measurement of anti-
BoNT/A1 immunoglobulins requires development of an original
assay based on the recognition of BoNT/A1 by these mAbs or
their fragments. In a previous study [20] we tested different
combinations of anti-BoNT/A1 mAbs to design an immunometric
assay. Among the pairs of mAbs able to bind BoNT/A1
simultaneously, some were tracer mAbs that recognized the same
epitope as mAbs tested in the pharmacokinetic study (TA12 and
TA17). When the sandwich assay was performed in the presence
of a tracer mAb and another unlabeled mAb, both directed against
the same epitope, there was competitive binding to the recom-
binant Hc BoNT/A1 immobilized on the plate via the capture
mAb. This reaction led to a signal decrease proportional to
the competitor concentration. To perform this assay, 50 ml of
recombinant Hc BoNT/A1 (2 ng/ml) were added to 50 ml of
mAb-AChE (2 EU/ml) and 100 ml of standard or samples, in
plates coated with the complementary mAb. For the TA12
quantification, we used TA5 as capture antibody and TA12-AChE
as tracer, while for TA17 we used TA16 as capture antibody and
TA13 as tracer. After 18-h incubation at 4uC and washing of the
plate, solid-phase bound AChE activity was revealed by the
addition of 200 ml of Ellman’s reagent for a 1-h reaction. The
absorbance of the wells was then measured at 414 nm.
Botulinum Antitoxine
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For accurate quantification, and depending on the experiments,
the different forms of antibody (mAb, F(ab’)2 or PEG-F(ab’)2)
injected in the mice were used as standard (Figure S1). The plasma
samples were diluted in 20-fold in EIA buffer and the standards
were prepared in plasma diluted 20-fold in EIA buffer. Higher
sample dilutions were made by dilution of diluted sample (1/20) in
diluted plasma (1/20). Each standard was analyzed in duplicate
and the blank (buffer alone) in octuplicate in order to determine
the minimum detectable concentration.
Pharmacokinetic studies
Balb\c mice (male, 30 g) were from the Centre d’élevage René
Janvier (Le Genest Saint Isle, France). An equivalent amount
(0.33 nmoles) of mAbs, F(ab)’2 or PEG-F(ab’)2 was injected in a
single intraperitoneal dose. For each post-dose time, blood samples
were collected from four animals by retro-orbital bleeding.
Animals that received mAbs were sampled at the following post-
dose times: 10 min, 4, 24, 48, 96, 240, 504 and 960 h. Animals
that received F(ab’)2 fragments were sampled at the following post-
dose times: 10, 30 min and 1, 2, 4, 8, 18 and 24 h. Animals that
received PEG-F(ab’)2 were sampled at the following post-dose
times: 30 min and 1, 4, 8, 18, 24, 48, 72, 96 and 240 h. Plasma
samples were assayed for mAb, Fab’2 or PEG-Fab’2 fragments
using the competitive sandwich procedure previously described. A
noncompartmental pharmacokinetic analysis was performed on
concentration-time data using the WinNonlin program.
Evaluation of mAb (ascitic fluid) neutralizing activity
The neutralizing capacity of the antibodies was evaluated in the in
vivo mouse lethality test. Neutralization tests were performed using
acid-precipitated toxins from strain Hall (type A1). Ten-fold serial
dilutions of the fourteen mAbs were incubated with botulinum toxin
type A1 containing approximately 10 mouse 50% lethal doses
(MLD50/ml) (Table S2), in 50 mM phosphate buffer pH 6.5
containing 1% gelatin (PB-G), for 30 min at room temperature. The
mixtures (0.5 ml) were then injected intraperitoneally (i.p.) into
Swiss mice weighing 20–22 g (4 mice per group). Mice were
observed and any deaths recorded every day for 4 days.
Neutralizing activity of TA12, TA17 and their fragments
The neutralizing capacity of the antibodies was evaluated in the in
vivo mouse lethality test. Neutralization tests were performed using
acid-precipitated toxins from strain Hall (type A1), strain 136.06
(type A2; GenBank HM135956) and strain Loch Maree (type A3).
Ten-fold serial dilutions of TA12, TA17 mAbs or their fragments
were incubated with botulinum toxin type A1, A2 or A3 containing
approximately 10 mouse 50% lethal doses (MLD50/ml) (Table S2),
in PB-G, for 30 min at room temperature. The mixtures (0.5 ml)
were then injected i.p. into Swiss mice weighing 20–22 g. Groups of
6–12 mice were used in three independent assays. Mice were
observed and any deaths recorded every day for 4 days.
Neutralizing activity using co-injection protocol
The purpose of this experiment was to determine the
neutralizing activity of TA12 mAb and its F(ab’)2 fragments,
before and after pegylation, co-injected with the toxin without
preincubation.
The neutralizing capacity of the antibodies was evaluated in the in
vivo mouse lethality test. 5 estimated MLD50 of BoNT/A1 in PB-G
(0.5 ml) were injected i.p. into Swiss mice weighing 20–22 g (6 mice
per group). Concomitantly, 0.5 ml of various dilutions of mAbs or
Table 1. BoNT/A1 neutralization activity of crude ascite fluids
from 14 mAbs in the mouse protection assay (5 estimated
MLD50/mouse).
Epitopic group Antibody Isotype Protective titer
A TA2 IgG1 104
TA10 IgG1 103
TA11 IgG1 104
TA12 IgG1 105
TA14 IgG1 104
B TA4 IgG2a 104
TA7 IgG2a 104
TA13 IgG2a 103
TA17 IgG2a 104
C TA1 IgG1 #102
TA5 IgG1 #102
TA15 IgG1 #102
D TA9 IgG1 102
E TA16 IgG1 103
The protective titer is the highest dilution of the ascitic fluid that completely
protected against 5 estimated MLD50 of BoNT/A1 in the mouse protection
assay.
Underline: non-neutralizing antibodies. Three ml of 10 estimated MLD50/ml
BoNT/A1 were incubated with 30 ml of serial ten-fold dilutions of ascitic fluid for
30 min at room temperature. 500 ml of the mixtures were injected
intraperitoneally to give final toxin challenges of approximately 5 MLD/50 into
each mouse of a group of 4 for each dilution.
doi:10.1371/journal.pone.0012416.t001
Table 2. BoNT/A1 neutralization activity of four purified monoclonal antibodies.
Epitopic group Antibody Ig concentration (mg/ml) Protective titer Lowest protective amount*
A TA12 0.442 105 2.2 ng
B TA17 1.4 103 700 ng
D TA9 0.595 102 ,3 mg
E TA16 0.608 102 ,3 mg
The protective titer is the highest dilution of the purified antibody that allows the neutralization of 5 estimated MLD50 of BoNT/A1 neurotoxin in the mouse protection
assay.
Ten-fold dilutions were used to generate final antibody concentrations ranging from 2.21 ng-2.21 mg/mouse for TA12, 700 ng-7 mg for TA17, 5.9 mg for TA9, and 6.1 mg
for TA16. These dilutions were incubated with toxin for 30 min and 0.5 ml was injected to give final toxin challenges of approximately 5 MLD50/mouse of a group of 4
for each dilution.
*Lowest amount of antibody needed to completely protect the mice against a 5 estimated MLD50 toxin.
doi:10.1371/journal.pone.0012416.t002
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their fragments in PB-G was injected i.p. into a close but different site.
Mice were observed and any deaths recorded every day for 4 days.
Time-course of clinical signs
5 estimated MDL50 of BoNT/A1 were injected i.p. into 8 Swiss
mice and the clinical signs of botulism were then recorded every
half hour for 8 hours.
Influence of the interval between toxin and anti-toxin
injections
Four groups of 17 to 18 mice for TA12 mAb and 4 groups of 10
mice for the F(ab’)2 and PEG-F(ab’)2 fragments were used. At
T = 0, 5 estimated MDL50 of BoNT/A1 were injected i.p. into
each mouse. The antitoxin was then injected i.p. after 0, 2, 4 or
6 hours, depending on the group of mice. For the experiment, we
used antitoxin equivalent to 100 times the dose which protected
100% of the mice challenged with 5 estimated MLD50 in the co-
injection experiment. Botulism symptoms and deaths were
recorded for 4 days.
Results
Measurement of BoNT/A1 neutralizing activity
In a previous study [20] using a monoclonal antibody
complementary test (Table S1), we classified the 14 mAbs
produced against the Hc BoNT/A1 protein into 5 distinct epitopic
groups. Groups A, B and C contain 5 mAbs (TA2, TA10, TA11,
TA12 and TA14), 4 mAbs (TA4, TA7, TA13 and TA17) and
3 mAbs (TA1, TA5, TA15), respectively, while the groups D and
E include a single mAb only (TA9 and TA16, respectively). As
shown in Table 1, ascitic fluids from most of these mAbs (12/14)
have neutralizing activity. It is noteworthy that although all the
mAbs recognized BoNT/A1 by ELISA, the mAbs of group C
exhibited very low or even no neutralizing activity. As the
immunoglobulin (Ig) content of ascitic fluids may vary from 1 to
10 mg/ml, we repeated the same experiment with the most potent
mAb of each group after purification to compare more precisely
the neutralization activity of the different mAbs (Table 2).
This experiment emphasized the great potency of TA12 mAb in
neutralizing BoNT/A1 toxicity in mice, since 2.2 ng of antibody
completely protected mice against an 5 estimated LD50 challenge
of BoNT/A1. In order to compare the protective activity of TA12
mAb with other recent reported mAbs, we also studied the ability
of a fixed amount of TA12 antibody (50 mg/mouse) to protect
mice challenged with increasing amount of BoNT/A1 ranging
from 100–10,000 MLD50 (Figure 1A). In this experiment, TA12
mAb showed a significant in vivo protection when mice were
challenged with 1,000 MLD50. As combinations of several mAbs
neutralize more efficiently than individual mAbs [11], we tested
different combinations of TA12 mAb with other neutralizing
mAbs of other groups. We failed to find a higher neutralization
titer than that obtained using TA12 mAb alone. TA12 was also
titrated with the reference L+10 method (European Pharmaco-
poeia 01/2008:0085) and international standard antitoxin A
(NIBSC 59/21) and a titer of 6 to 20 IU/mg of antibody was
obtained (by definition, an International Unit (IU) neutralizes
16104 MLD50). Again, in order to compare the protective activity
with other reported mAbs, the potency of TA12 was also titrated
using the standard mouse bioassay described by Hatheway and
Dang [22] and was determined to be 286 UI/mg of Ab. Since it
has been found that the neutralization activity of anti-BoNT/A
antibodies is not linear using various challenge doses, the
protective activity of TA12 was determined with several BoNT/
A1 doses (Figure 1B). As the toxin challenge increases, the level of
TA12 needed to completely protect mice also increased and
appeared to reach a maximum at approximately above 50 mg of
antibody and 1,000 MLD50 (Figure 1B). This experiment also
showed that the protective activity of TA12 is not linear over the
range of 5–2,000 MLD50. For further studies, 2 mAbs were
selected: TA12, since it has the highest BonT/A1 neutralizing
activity, and TA17, which is quite efficient and recognizes a
different epitope than TA12.
BoNT/A2 and/A3 neutralizing activity of TA12 and TA17
As currently defined, BoNT/A consists of various subtypes
[23–25]. Amino acid sequence variations within BoNT/A
subtypes are around 15% or less and have been reported to
Figure 1. BoNT/A1 neutralization activity of TA12 mAb. A. TA12
mAb (50 mg/mouse) was incubated with variable amounts of BoNT/A1
from 100 to 5,000 estimated MLD50/mouse and the mixtures were
intraperitoneally injected to groups of 12 mice each. The number of
mice surviving versus challenge is indicated. TA12 mAb (50 mg)
protected approximately 1,000 estimated MLD50. B. Protective doses
of TA12 mAb with increasing BoNT/A1 challenge doses. Protective
potency of various doses of TA12 mAb (0.0025, 1, 50, 1,000 mg/mouse)
was determined by incubation with various BoNT/A1 challenge doses.
The mixtures were injected intraperitoneally to groups of 12 mice. The
protective TA12 mAb doses protecting 90 to 100% mice are plotted
versus BoNT/A1 challenge doses. Note that increasing amounts of TA12
mAb are required to neutralize increased BoNT/A1 challenge doses,
specially above 1,000 estimated MLD50.
doi:10.1371/journal.pone.0012416.g001
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impact on antibody binding and neutralization [26]. We therefore
studied the capacity of the purified TA12 and TA17 mAbs to
neutralize subtypes other than A1, such as BoNT/A2 and BoNT/
A3. As depicted in Table 3, TA12 and TA17 mAbs showed a
marked (10- to 100-fold) reduction in capacity to neutralize
BoNT/A2 and BoNT/A3, compared with BoNT/A1.
F(ab’)2 pegylation
The protocol used for the pegylation process was quite simple,
but resulted in several species of PEG-F(ab’)2 (one or several PEG
molecules per F(ab’)2) and no native F(ab’)2, as revealed by SDS-
PAGE electrophoresis (data not shown). In order to purify each
PEG-F(ab’)2 species, we used a cation exchange matrix, allowing
Table 3. Neutralization activity of TA12 and TA17 mAbs with BoNT/A subtypes.
mAb quantity (ng/mouse) 2,500 250 25 2.5 0.25
mAb quantity (ng/mouse) giving
50% neutralization activity
TA12 BoNT/A1 0/10 0/10 0/10 0/10 10/10 0.25,5
BoNT/A2 0/9 6/9 9/9 ND ND 250
BoNT/A3 0/9 0/9 6/9 ND ND 25
TA17 BoNT/A1 0/10 0/10 10/10 ND ND 25,250
BoNT/A2 3/9 10/10 10/10 ND ND 2 500
BoNT/A3 10/10 10/10 8/10 ND ND .2 500
ND: not determined
MAb neutralization activity was determined using the mouse protection assay with 5 estimated MLD50/ml of BoNT/A1, BoNT/A2 or BoNT/A3 and serial dilutions of
mAbs.
5 estimated MLD50/mouse were incubated for 30 min at room temperature with 2,500 to 0.25 ng of mAb and the mixture (0.5 ml) was injected intraperitoneally in each
mouse of a group of 9 to 10 mice.
Results are expressed as the number of dead mice versus the total number of mice and are from three independent experiments.
doi:10.1371/journal.pone.0012416.t003
Figure 2. Elution profile of PEG-F(ab’)2. — UV detection at 280 nm; ----- NaCl concentration; P1, P2, P29, P3, P39, P4, P5 and P6 correspond to the
different peaks collected during the chromatography purification. After conjugation of F(ab’)2 to the N-hydroxysuccinimidyl ester of methoxy
poly(ethylene glycol) butanoic acid (NHS-PEG), the different F(ab’)2 species were purified by cation exchange chromatography. This purification
removed unreacted NHS-PEG and separated the different F(ab’)2 species (nonpegylated, monopegylated and multipegylated F(ab’)2). A MacroCap SP
column (GE Healthcare), (10.561 cm) was used with an AKTÄ system (GE Healthcare) and equilibrated with buffer A (0.02 M acetate buffer pH 5) at a
flow rate of 1 ml/min. The pegylated F(ab’)2 were eluted using successive gradient steps of 12 ml each at 2, 3, 4, 5 and 25% of buffer B (0.02 M
acetate buffer pH 5 + 1 M NaCl) at a flow rate of 1 ml/min. During the chromatography, fractions of 1 ml were collected and the absorbance was
monitored at 280 nm.
doi:10.1371/journal.pone.0012416.g002
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the purification of large pegylated molecules. The chromato-
graphic pattern of the PEG-F(ab’)2 purification monitored at
208 nm is shown in Figure 2. The purity of each peak was assessed
by SDS-PAGE (Figure 3). As shown in Figure 3, a good separation
of PEG-F(ab’)2 was obtained using a multi-step gradient; no native
F(ab’)2 was recovered. Since a rather low molar ratio of PEG
activated ester was used, this result is a bit surprising. During the
chromatographic experiment the different PEG-F(ab’)2 species
were eluted depending on their degree of pegylation: the more
pegylated species were eluted faster. As indicated in the intro-
duction section, production of PEG-F(ab’)2 was chosen because
this process easily increases the (Fab)’2 in vivo half-life. As the aim of
this production was to increase the in vivo half-life of the F(ab’)2
fragments and not to study the effect of the degree of pegylation,
which has already been investigated by other groups, the different
fractions containing PEG-F(ab’)2 were pooled for the subsequent
experiments. This allowed us to obtain a larger amount of PEG-
F(ab’)2 starting from the same amount of F(ab’)2.
Pharmacokinetic studies
The concentrations of mAb, F(ab’)2 and PEG-F(ab’)2 in the
plasma of mice (n = 4) versus time are depicted in Figure 4. The
calculated half-lives in plasma for TA12 mAb, TA12 F(ab’)2,
TA12 PEG-F(ab’)2, TA17 mAb, TA17 F(ab’)2 and TA17 PEG-
F(ab’)2 were 22, 0.17, 1.5, 5.1, 0.54 and 1.25 days, respectively.
These results clearly show that the pegylation increased the
half-life of the F(ab’)2 fragments. Compared with unmodified
F(ab’)2, the terminal half-life of PEG-F(ab’)2 was increased 9- and
3-fold for TA12 and TA17, respectively.
Neutralizing activity of the mAbs and their fragments
The BoNT/A1-neutralizing activities of mAbs and their
fragments are summarized in Tables 4 and 5. Unlike mAb
TA12, which had the same neutralizing titer whatever its form, the
neutralizing titer of the TA17 antibody decreased 10-fold when
using F(ab’)2 fragments, pegylated or not. It is worth noting that
the pegylation step did not modify the neutralization capacity of
either of these antibodies. On the other hand, TA12 mAb and its
fragments had a much greater neutralizing activity than TA17
mAb and its fragments: 100-fold for the whole antibody and
1,000-fold for the fragments. Therefore, we decided to study the
therapeutic activity of TA12 mAb and its fragments.
Therapeutic Study
Neutralizing activity using co-injection. As shown in
Table 6, the amount of antibody required to neutralize 5
estimated MDL50 of BoNT/A1 was 10 times higher when the
toxin was co-injected with the antibody than when seroneu-
tralization is performed in vitro before injection of the mixture
(25 ng of mAb/mouse and 2.5 ng of mAb/mouse, respectively).
This observation is true whatever the antibody forms (mAb, F(ab’)2
or PEG-F(ab’)2).
Figure 3. SDS-PAGE analysis of the PEG-F(ab’)2 chromatography peaks. P1, P2, P29, P3, P39, P4, P5 and P6 correspond to the different peaks
recorded during the chromatography purification. KDa: KiloDalton After conjugation of F(ab’)2 to the N-hydroxysuccinimidyl ester of methoxy
poly(ethylene glycol) butanoic acid (NHS-PEG), the different F(ab’)2 species were purified by cation exchange chromatography. This purification
removed unreacted NHS-PEG and separated the different F(ab’)2 species (nonpegylated, monopegylated and multipegylated F(ab’)2).
doi:10.1371/journal.pone.0012416.g003
Botulinum Antitoxine
PLoS ONE | www.plosone.org 6 August 2010 | Volume 5 | Issue 8 | e12416
This result seems consistent with the preincubation step used
during the standard bioassay which favors the formation of toxin/
antitoxin complexes, and thus the efficiency of neutralization.
Time course of clinical signs. The time course of the onset
of clinical signs varied according to the mice (Table 7). The first
clinical signs (skinny or paralyzed mouse) appeared after 4 to
8 hours. The death of the first mouse was observed after 7 hours
(1/7). All the mice presenting clinical signs died within 24 hours.
Influence of the interval between toxin and antitoxin
injections on mouse survival rate. Mouse survival rate as a
Figure 4. Mean concentration-time profiles following administration of 0.33 nmoles of mAb, F(ab’)2 or PEG-F(ab’)2. An equivalent
amount (0.33 nmoles) of mAbs, F(ab)’2 or PEG-F(ab’)2 was injected in Balb\c mice in a single intraperitoneal dose. For each post-dose time, blood
samples were collected from four animals by retro-orbital bleeding. Animals that received mAbs were sampled at the following post-dose times:
10 min, 4, 24, 48, 96, 240, 504 and 960 h. Animals that received F(ab’)2 fragments were sampled at the following post-dose times: 10, 30 min and 1, 2,
4, 8, 18 and 24 h. Animals that received PEG-F(ab’)2 were sampled at the following post-dose times: 30 min and 1, 4, 8, 18, 24, 48, 72, 96 and 240 h.
Plasma samples were assayed for mAb, Fab’2 or PEG-Fab’2 fragments.
doi:10.1371/journal.pone.0012416.g004
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function of the interval between toxin and antitoxins is sum-
marized in Table 8. When 5 estimated MDL50 of BoNT were
injected i.p. at the same time as 2.5 mg of antitoxin, the survival
rate was approximately 90%, whatever the nature of the antitoxin
(whole mAb, F(ab’)2 or PEG-F(ab’)2). This rate decreased as the
time between toxin and antitoxin injections increased: 70% for
2 h, 20 to 40% for 4 or 6 h. It should be noted that for an interval
of 6 hours, when the clinical signs were well established, 30 to 40%
of the animals survived and recovered gradually without additional
treatment.
Discussion
As previously shown by different groups [19,27,28], the use of
the BoNT binding domain as immunogen allows production of a
high ratio of neutralizing mAbs. In this study, 12 out of 14 mAbs
presented neutralizing activity and recognized 4 different epitopes
of the toxin-binding domain, which was used as antigen. Among
these mAbs, TA12 had the highest neutralizing activity (Table 1).
In contrast to the results reported by Nowakowski et al. [11], who
reported increased neutralization efficiency for a combination
of three mAbs, none of the combinations of TA12 with other
neutralizing mAbs were more potent. This may be because of the
already high neutralizing capacity of TA12 (6 to 20 IU/mg using
the reference L+/10 method or 286 IU/mg by the method from
Hatheway and Dang [22]), which alone is as efficient, or slightly
less so, as other antibodies reported in the literature, such as an
oligoclonal antibody (45 IU/mg, [11]), a hyperimmune mono-
serotype horse type antitoxin (39 IU/mg [29]), and a caprine
pentavalent polyclonal (6.8 IU/mg, [5]). TA12 is also more potent
than the human botulinum immune globulins used to treat infant
botulism [30]. To the best of our knowledge, TA12 exhibits the
highest neutralization potency described for a single mAb as a
BoNT/A1 antitoxin. However, the mouse lethal bioassay could be
influenced by factors like season, strain of mouse, diet, toxin
dilution buffer, bacterial strain producing the toxin, toxin chal-
lenge dose and route of injection [5]. So the comparison between
the potency of different antitoxins obtained by different groups is
questionable.
Recently, variability of BoNT/A protein sequence has been
reported and at least 5 subtypes have been identified: BoNT/A1/
A2/A3/A4/A5 [31] [25]. A recent report [26] has shown that the
variability within subtypes A1 and A2 (around 10%) could reduce
the neutralizing potency of mAbs raised against recombinant Hc
BoNT/A1, from .40, 000 mouse MLD50 to 500 MLD50. In light
of these observations, we decided to evaluate the neutralizing
potency of TA12 mAb with BoNT/A2 and BoNT/A3. The
neutralizing activities obtained were 10- and 1,000-fold less for
BoNT/A2 and A3 subtypes, respectively, compared with BoNT/
A1 (Table 3). Combinations of our mAbs may possibly increase
the potency of neutralization of BoNT/A2 and BoNT/A3, as
already described [11]. It is worth noting that the neutralization
assays were performed with a 5 estimated MLD50 challenge of
each BoNT subtype, since no international reference serum is
available for titration of BoNT/A2 and BoNT/A3 antibodies by
the reference L+10 method.
The main goal of this study was to evaluate the impact of the
different antitoxin forms (whole antibody, F(ab’)2 and PEG-F(ab’)2)
on their neutralizing efficiency. The procedures used to modify the
F(ab’)2 lead to several species of PEG-F(ab’)2 with different degrees
of pegylation. The pharmacokinetic study of these antitoxins
showed that the pegylation process increased the half-life of F(ab’)2
Table 4. Neutralizing potency of the TA12 mAb and its F(ab’)2 and PEG- F(ab’)2 fragments.
Antibody and antibody
fragment mAb (ng/mouse)
mAb (ng/mouse) giving 50%
neutralization activity
2,500 250 25 2.5 0.25 0.025
TA12 mAb 0/10 0/10 0/10 4/10 6/8 6/8 2.5
F(ab’)2 0/10 0/10 2/10 3/9 8/8 8/8 2.5
PEG-F(ab’)2 0/10 0/10 0/10 2/8 6/8 8/8 0.25,2.5
The mAb neutralizing activity was determined using the mouse protection assay with 5 estimated MLD50/mouse of BoNT/A1.
5 estimated MLD50/mouse were incubated for 30 min at room temperature with 2,500 to 0.025 ng of mAb and the mixture (0.5 ml) was injected intraperitoneally in
each mouse of a group of 8 mice.
Results are expressed as the number of dead mice versus the total number of challenged mice and are from three independent experiments
doi:10.1371/journal.pone.0012416.t004
Table 5. Neutralizing potency of the TA17 mAb and its F(ab’)2 and PEG- F(ab’)2 fragments.
Antibody and antibody
fragment mAb (ng/mouse)
mAb (ng/mouse) giving 50%
neutralization activity
8,333 2,500 500 250 50
TA17 mAb 0/8 0/8 0/8 0/8 8/8 50,250
F(ab’)2 0/8 8/8 6/8 8/8 ND 2,500,8,333
PEG-F(ab’)2 0/8 4/8 6/8 6/8 ND 2,500,8,333
ND: not determined
The mAb neutralizing activity was determined using the mouse protection assay with 5 estimated MLD50/mouse of BoNT/A1.
5 estimated MLD50/mouse were incubated for 30 min at room temperature with 8,333 to 50 ng of mAb and the mixture (0.5 ml) was injected intraperitoneally in each
mouse of a group of 8 mice.
Results are expressed as the number of dead mice versus the total number of challenged mice and are from three independent experiments.
doi:10.1371/journal.pone.0012416.t005
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for both antibodies evaluated. Although the molecular weight of
F(ab’)2—98 k Da—is already above the limit of the glomerular
filtration cut-off (approximately 70 kDa), the increased half-life of
pegylated products may be partly explained by an increase in
molecular weight, further resulting in a decrease in urinary
clearance. This may be supported by the results reported by Knauf
et al [32] and Koumenis et al. [14] showing a relationship between
the clearance rate and the molecular weight of pegylated
molecules up to 200 kDa and 1.9 million Da, respectively. This
relationship could also be explained by several other mechanisms,
like shape alteration and protein charge induced by pegylation.
On the other hand, whole immunoglobulins G have a higher half-
life probably because their clearance is slower than that of their
respective fragments. This is probably due to specific Hc inter-
actions with receptors like HcRn which protect IgG from
catabolism [33,34].
By contrast with TA17 mAb, the production of F(ab’)2 fragment
from TA12 mAb by pepsinolysis did not modify the neutralizing
activity. Moreover, as reported by Koumenis et al. [14], the random
pegylation of the F(ab’)2 fragments of both mAbs by amine reactive
chemistry did not affect the biological activity. Considering these
results, the therapeutic study was performed only with the TA12
mAb and its fragments, since these compounds were at least 100
times more efficient than the TA17 counterparts.
The time course of the onset of clinical signs induced by BoNT/
A injection defines the optimal timing of antitoxin injection and
the clinical course after treatment. Using the data of co-injection
experiments, the impact of the interval between toxin and
antitoxin injections on the survival rate was evaluated. This study
showed that the various forms of TA12 mAb were equally
efficient. Amazingly, the 4-h interval using PEG-F(ab’)2 resulted in
a poorer survival rate, which is difficult to explain considering the
data for the 6-h interval and may result from an experimental
artifact. These results strongly suggest an absence of correlation
between the half-life of the antitoxins and the timing of treatment
after contamination. This seems consistent with the time required
for the toxin and antitoxin to reach their action sites (neuromus-
cular junctions for the toxin, blood and neuromuscular junctions
for the antitoxin) and with the mode of action of the antitoxin. In
our study, TA12 mAb, which has been raised with Hc BoNT/A1,
or its fragments presumably neutralized BoNT by preventing its
binding to the cellular membrane receptors (gangliosides and
proteins), the step preceding its internalization. Internalization
further prevents the toxin from interacting with mAbs, which can
therefore only act efficiently during the initial step, i.e. when the
toxin is free, by blocking toxin binding to its receptors. It is
noteworthy that in human intoxication by the oral route or aerosol
the incubation period is longer (12 h to 7 days) than in the murine
experimental model and, moreover, the amount of ingested or
inhaled toxin can be lower than the lethal dose. In these cases, the
administration of antibody to exposed subjects is still indicated to
prevent botulism effectively. However, when the clinical signs are
present, the time scale allowing effective action of botulinum
antibody antitoxin is very short, if it is not already too late.
Despite these results, since the biological activity of mAbs could be
altered by the F(ab’)2 production, as already observed with TA17
Table 6. Neutralizing potency of the mAb TA12 and its F(ab’)2 and PEG-F(ab’)2 fragments using the co-injection protocol.
TA12 form mAb (ng/mouse)
mAb (ng/mouse) giving 50% neutralization
activity
2,500 250 25 2.5 0.25 0.025
mAb 0/6 2/6 1/6 4/6 3/6 6/6 2.5,25
F(ab’)2 ND ND 0/6 3/6 6/6 6/6 2.5,25
PEG-F(ab’)2 ND ND 0/6 3/6 3/6 6/6 2.5,25
ND: not determined
The mAb neutralizing activity was determined using the mouse protection assay with 5 estimated MLD50/mouse of BoNT/A1. BoNT/A1 (0.5 ml) and serial dilutions of
mAb or its fragments (0.5 ml) were injected separately into each mouse of a group of 6. Results are expressed as the number of dead mice versus the total number of
challenged mice.
doi:10.1371/journal.pone.0012416.t006
Table 7. Time course of clinical signs after botulinum toxin
type A injection (5 estimated MLD50/mouse).
Mouse
#
Before
4 h 4 h 5 h 5.5 h 6 h 6.5 h 7 h 7.5 h 8 h 24 h
1 No sign A A A A A A A A A
2 No sign S S P P P P P M D
3 No sign S S P P P P M M D
4 No sign S S S S S S S P D
5 No sign S S P P P P M M D
6 No sign P P P M M D D D D
7 No sign S P P P P M M M D
8 No sign S S S P P P P M D
A: Alive; S: Skinny; P: Paralyzed; M: Motionless; D: Dead
The indicated times correspond to the time after botulinum toxin injection
doi:10.1371/journal.pone.0012416.t007
Table 8. Influence of the interval between toxin and antitoxin
injections on survival rate (values in brackets).
Antitoxin form 0 hours 2 hours 4 hours 6 hours
TA12 mAb 16/17 (94%) 12/18 (67%) 9/18 (50%) 5/18 (28%)
TA12 F(ab’)2 9/10 (90%) 8/10 (80%) 4/10 (40%) 4/10 (40%)
TA12 PEG-F(ab’)2 9/10 (90%) 7/10 (70%) 2/10 (20%) 4/10 (40%)
The indicated times correspond to the interval between toxin and antitoxin
injections.
At T = 0 5 estimated MDL50 of botulinum toxin type A1 (0.5 ml) were injected
i.p. into all mice. The antitoxin was then injected i.p. into mice after 0, 2, 4 or
6 hours. An amount of antitoxin (2.5 mg/mouse) equivalent to 100 times the
dose which protected 100% of the mice challenged with 5 estimated MLD50 in
the co-injection experiment was used. Botulism symptoms and mortality were
recorded for 4 days. Results are expressed as the number of dead mice versus
the total number of challenged mice.
doi:10.1371/journal.pone.0012416.t008
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mAb in the present study, or by F(ab’)2 pegylation [17], the
production of chimeric or humanized antibodies is still a good
alternative to production of human anti-mouse antibodies. In terms
of the prophylactic use of these antitoxins, it should be kept in mind
that their half-life is the key parameter for the duration of protection.
In conclusion, the present study shows that while pegylation
increases the half-life of F(ab’)2 without altering its neutralizing
efficiency, it does not improve therapeutic treatment after BoNT/
A1 injection, as compared with the initial F(ab’)2 or mAb.
Moreover, our results show that, in a mouse model, treatment can
still be effective with a 2- to 4-h interval between toxin and
antitoxin injection.
Finally, these results demonstrate the need to make the
diagnosis and to perform toxinotyping of botulism as fast as
possible in order to expedite adaptation of the antitoxin treatment.
Supporting Information
Figure S1 Examples of standard curves obtained for competitive
sandwich assay of TA12 species (mAb, F(ab’)2 or PEG-F(ab’)2) in
diluted plasma. &: TA12 mAb; .: TA12 F(ab’)2; m: TA12 PEG-
F(ab’)2. The competitive sandwich assay is performed in the
presence of a mAb tracer and another unlabeled mAb or
fragment, both directed against the same epitope. There was
competitive binding to the recombinant Hc BoNT/A1 immobi-
lized on the plate by the capture mAb. This reaction leads to a
signal decrease proportional to the competitor concentration. To
perform this assay, 50 ml of recombinant Hc BoNT/A1 (2 ng/ml),
50 ml of TA12-acetylcholinesterase (AChE) and 100 ml of different
concentrations of TA12 species (mAb, F(ab’)2 or PEG-F(ab’)2)
were added to plates coated with TA5. The TA12 species were
dilutions were made in diluted mouse plasma (1/20). After 18-h
incubation at 4uC and washing of the plate, solid phase-bound
AChE activity was revealed by the addition of 200 ml of Ellman’s
reagent for a 1-h reaction. The absorbances of the wells were then
measured at 414 nm.
Found at: doi:10.1371/journal.pone.0012416.s001 (0.81 MB TIF)
Table S1 Signals obtained for monoclonal antibody comple-
mentary tests. +++: Signals .1 absorbance unit; ++: Signals
between 1 and 0.5 absorbance unit; +: Signals between 0.5 and 0.1
absorbance unit; +/2: Signals ,0.1 absorbance unit; White
squares: No specific signal. The simultaneous binding of the
different mAbs to BoNT/A was analyzed in immunometric tests,
with one mAb immobilized on the solid phase while the other was
used tracer. Experiments were performed as follows: 10 ng/ml
BoNT/A and 100 ml of a 100 ng/ml mAb tracer solution were
added to microtitre plate wells coated with one of the mAbs. After
18-h incubation at 4uC, the plates were washed and the mAb
tracer signal was measured (colorimetric signal).
Found at: doi:10.1371/journal.pone.0012416.s002 (0.07 MB
DOC)
Table S2 Toxin calibration. Toxin preparations were diluted in
phosphate/gelatin buffer to obtain 5 estimated MLD/mouse and
were checked as follows: 500 ml of toxin dilution were injected
intraperitoneally into each mouse of a group of 3 to 4 mice.
Results are expressed as the number of dead mice versus the total
number of mice and are from 8 to 15 independent experiments.
Found at: doi:10.1371/journal.pone.0012416.s003 (0.03 MB
DOC)
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